Home › Funds › Pale Fire Capital SE › NKTR
Pale Fire Capital SE position in NKTR
NEKTAR THERAPEUTICS · Health Care
Pale Fire Capital SE reported holding 6,050 shares of NKTR (NEKTAR THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$366K, representing 0.03% of its reported portfolio and ranking #39 among its reported holdings. Pale Fire Capital SE has disclosed NKTR holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Pale Fire Capital SE's NKTR position evolved
Pale Fire Capital SE first disclosed a stake in NKTR in Q2 2026 at 3,350 shares (US$234K). The position peaked in Q3 2026 at 6,050 shares, worth US$366K. Across 2 filings, Pale Fire Capital SE increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 6,050 shares valued at US$366K — an increase of 2,700 shares quarter over quarter.. Notable position changes include a 81% increase in Q3 2026 (shares fell 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 3.35K | $233.86K | New |
| Q3 2026 | 6.05K | $366.30K | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NKTR and 13F data
NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 57 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NKTR
- Two Seas Capital LP 3.35M sh · $202.58M · Q3 2026
- BVF INC/IL 2.39M sh · $166.92M · Q2 2026
- Vestal Point Capital, LP 1.00M sh · $69.81M · Q2 2026
- ARMISTICE CAPITAL, LLC 724.00K sh · $50.54M · Q2 2026
- Prosight Management, LP 785.00K sh · $47.53M · Q3 2026
- BRAIDWELL LP 473.62K sh · $33.06M · Q2 2026
- Sofinnova Investments, Inc. 471.76K sh · $32.93M · Q2 2026
- ORBIMED ADVISORS LLC 465.35K sh · $32.49M · Q2 2026
- DAFNA Capital Management LLC 318.38K sh · $22.23M · Q2 2026
- ADAR1 Capital Management, LLC 244.18K sh · $17.05M · Q2 2026
- 22NW, LP 281.12K sh · $17.02M · Q3 2026
- SEVEN GRAND MANAGERS, LLC 240.00K sh · $16.75M · Q2 2026
More on Pale Fire Capital SE
FAQ
How long has Pale Fire Capital SE held NKTR?
Pale Fire Capital SE has disclosed NKTR holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Pale Fire Capital SE's current position in NKTR?
As of Q3 2026, Pale Fire Capital SE holds 6.05K shares of NKTR (NEKTAR THERAPEUTICS), valued at $366.30K, representing 0.03% of its reported portfolio and ranking #39.
Has Pale Fire Capital SE been buying or selling NKTR?
In the latest 13F filing (Q3 2026), Pale Fire Capital SE increased its position in NKTR. The position peaked in Q3 2026 at 6.05K shares.
Which other funds hold NKTR?
Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 57 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.